In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for BT5528. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of BT5528 through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [2]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for CAR-T cells targeting EphA2. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of CAR-T cells targeting EphA2 through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [3]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [4]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-547. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of MEDI-547 through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [5]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [6]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Fascin (FSCN1) is a therapeutic target for NP-G2-044. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of NP-G2-044 through regulating the expression of Fascin (FSCN1).			[8], [9]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for D-glucose. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of D-glucose through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [11]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [12]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [13]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [14]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [15]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1).			[10], [16]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2).			[10], [17]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for HIF-1alpha. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of HIF-1alpha through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [19]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for IT-101. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of IT-101 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [20]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for 2-Methoxyestradiol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 2-Methoxyestradiol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [21]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PT2385. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of PT2385 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ENMD-1198. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ENMD-1198 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [23]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for EZN-2968. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of EZN-2968 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [24]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PX-478. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of PX-478 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [25]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [26]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 175510. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 175510 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298697. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298697 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298699. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298699 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298700. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298700 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298701. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298701 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298702. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298702 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298711. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298711 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298712. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298712 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298743. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298743 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298744. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298744 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298745. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298745 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298746. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ISIS 298746 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[18], [28]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Abacavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Abacavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Acebutolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Acebutolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Acrivastine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Acrivastine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Actinomycin D. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Actinomycin D through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Afatinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Afatinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [34]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ajmaline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ajmaline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [35]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Albendazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Albendazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [36]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Aldosterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Aldosterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [37]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Aliskiren fumarate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Aliskiren fumarate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [38]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ambrisentan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ambrisentan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [39]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amiodarone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amiodarone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amisulpride. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amisulpride through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amitriptyline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amitriptyline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amoxicillin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amoxicillin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amphotericin B. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amphotericin B through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Amprenavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Amprenavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Apixaban. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Apixaban through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [43]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Apremilast. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Apremilast through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Aprepitant. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Aprepitant through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Arsenic trioxide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Arsenic trioxide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [46]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Aspirin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Aspirin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Atenolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Atenolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Atomoxetine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Atomoxetine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Axitinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Axitinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Azasetron. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Azasetron through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Azathioprine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Azathioprine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Azithromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Azithromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [49]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Baloxavir marboxil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Baloxavir marboxil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Baricitinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Baricitinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [51]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Beclomethasone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Beclomethasone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Beclomethasone dipropionate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Beclomethasone dipropionate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bepridil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bepridil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for beta-Acetyldigoxin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of beta-Acetyldigoxin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [53]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for beta-Carotene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of beta-Carotene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Betamethasone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Betamethasone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Betrixaban. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Betrixaban through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [55]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bicalutamide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bicalutamide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [56]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Binimetinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Binimetinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [57]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Biotin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Biotin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [58]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Boceprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Boceprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bosutinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bosutinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Brilinta. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Brilinta through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bromocriptine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bromocriptine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bupropion. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bupropion through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cabergoline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cabergoline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [63]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Canagliflozin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Canagliflozin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cannabidiol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cannabidiol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Carfilzomib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Carfilzomib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [65]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Carvedilol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Carvedilol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cefoperazone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cefoperazone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cefotetan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cefotetan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ceftriaxone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ceftriaxone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Celiprolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Celiprolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [66]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cepharanthine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cepharanthine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [67]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ceritinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ceritinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [68]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cerivastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cerivastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cetirizine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cetirizine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [70]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Chlorambucil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Chlorambucil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Chloramphenicol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Chloramphenicol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Chlorpromazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Chlorpromazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ciclesonide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ciclesonide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cimetidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cimetidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cinchonidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cinchonidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cisplatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cisplatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Citalopram. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Citalopram through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clarithromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clarithromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clobazam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clobazam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clofazimine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clofazimine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomifene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clomifene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomiphene citrate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clomiphene citrate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomipramine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clomipramine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clonidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clonidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clopidogrel. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clopidogrel through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Clozapine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Clozapine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Colchicine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Colchicine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cortisone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cortisone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cyclosporine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cyclosporine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cytarabine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cytarabine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dabigatran. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dabigatran through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dabrafenib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dabrafenib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [79]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Daclatasvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Daclatasvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dactinomycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dactinomycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Darunavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Darunavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Debrisoquine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Debrisoquine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Deflazacort. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Deflazacort through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Delavirdine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Delavirdine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Desipramine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Desipramine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Desloratadine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Desloratadine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Diazepam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Diazepam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dicloxacillin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dicloxacillin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Diethylstilbestrol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Diethylstilbestrol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Digitoxin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Digitoxin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Digoxin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Digoxin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydroergocristine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dihydroergocristine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Diltiazem. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Diltiazem through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dipyridamole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dipyridamole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Docetaxel. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Docetaxel through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dolutegravir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dolutegravir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Domperidone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Domperidone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Doxycycline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Doxycycline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ebastine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ebastine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Edoxaban. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Edoxaban through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [91]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Efavirenz. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Efavirenz through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Eletriptan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Eletriptan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Eliglustat tartrate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Eliglustat tartrate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Emetine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Emetine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Empagliflozin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Empagliflozin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Epinastine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Epinastine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Epirubicin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Epirubicin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ergotamine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ergotamine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Erythromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Erythromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [93]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Eslicarbazepine acetate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Eslicarbazepine acetate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [94]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Estradiol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Estradiol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Estriol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Estriol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Estrone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Estrone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Estrone sulfate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Estrone sulfate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ethinyl estradiol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ethinyl estradiol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Etoposide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Etoposide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [96]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ezetimibe. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ezetimibe through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Famciclovir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Famciclovir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Felodipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Felodipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [98]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fentanyl. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fentanyl through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fesoterodine fumarate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fesoterodine fumarate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [99]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fexofenadine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fexofenadine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [100]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluoxetine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fluoxetine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [101]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Flupentixol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Flupentixol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluphenazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fluphenazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluticasone propionate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fluticasone propionate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluvastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fluvastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluvoxamine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fluvoxamine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Folic acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Folic acid through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [102]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fosamprenavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fosamprenavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Gatifloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Gatifloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [103]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Gilteritinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Gilteritinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Glutathione. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Glutathione through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [104]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Gramicidin D. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Gramicidin D through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Grepafloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Grepafloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Guanabenz. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Guanabenz through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Guanfacine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Guanfacine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [105]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Haloperidol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Haloperidol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydrocortisone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Hydrocortisone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydroxyurea. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Hydroxyurea through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ibrutinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ibrutinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [106]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Idarubicin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Idarubicin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [107]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Imatinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Imatinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [108]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Imipramine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Imipramine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Indacaterol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Indacaterol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Indinavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Indinavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [109]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Indomethacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Indomethacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [110]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ingenol-3-angelate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ingenol-3-angelate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [111]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Irinotecan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Irinotecan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [112]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Itraconazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Itraconazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivacaftor. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ivacaftor through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [113]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivermectin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ivermectin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [114]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivosidenib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ivosidenib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [115]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ixabepilone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ixabepilone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [116]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ketoconazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ketoconazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for L-tryptophan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of L-tryptophan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [117]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Labetalol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Labetalol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lamotrigine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lamotrigine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [118]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lansoprazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lansoprazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lapatinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lapatinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ledipasvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ledipasvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lenalidomide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lenalidomide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [119]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lenvatinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lenvatinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [120]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Levetiracetam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Levetiracetam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [121]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Levodopa. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Levodopa through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Levofloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Levofloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Levomepromazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Levomepromazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Levomilnacipran. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Levomilnacipran through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [122]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lidocaine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lidocaine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Linagliptin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Linagliptin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Loperamide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Loperamide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [123]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lopinavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lopinavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [124]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Loratadine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Loratadine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Losartan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Losartan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [125]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lovastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lovastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Lovastatin acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Lovastatin acid through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Maraviroc. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Maraviroc through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mefloquine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mefloquine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [126]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Melphalan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Melphalan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [127]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Meperidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Meperidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [128]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mequitazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mequitazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Methadone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Methadone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [129]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Methotrexate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Methotrexate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Methylprednisolone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Methylprednisolone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [130]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Methysergide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Methysergide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Midazolam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Midazolam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Midostaurin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Midostaurin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mitomycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mitomycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [131]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mitoxantrone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mitoxantrone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Morphine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Morphine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [132]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Moxidectin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Moxidectin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [133]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mycophenolate mofetil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nadolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nadolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nalbuphine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nalbuphine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Naloxegol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Naloxegol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nelfinavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nelfinavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [135]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Neostigmine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Neostigmine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nevirapine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nevirapine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nicardipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nicardipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nifedipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nifedipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nilotinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nilotinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nimodipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nimodipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nintedanib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nintedanib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [137]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nisoldipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nisoldipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nitrendipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nitrendipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nizatidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nizatidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [138]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Norfloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Norfloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Olanzapine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Olanzapine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Olmesartan medoxomil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Olmesartan medoxomil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Olopatadine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Olopatadine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Omadacycline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Omadacycline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [139]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ombitasvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ombitasvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Omeprazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Omeprazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ondansetron. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ondansetron through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [126]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Oseltamivir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Oseltamivir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [140]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Oxcarbazepine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Oxcarbazepine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [141]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Palbociclib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Palbociclib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Paliperidone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Paliperidone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [143]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Panobinostat. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Panobinostat through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [144]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pantoprazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pantoprazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Paroxetine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Paroxetine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pazopanib hydrochloride. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pazopanib hydrochloride through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [145]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pemirolast. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pemirolast through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pentazocine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pentazocine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Perazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Perazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Perphenazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Perphenazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenobarbital. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Phenobarbital through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [141]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenprocoumon. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Phenprocoumon through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [146]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenytoin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Phenytoin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [141]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pibrentasvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pibrentasvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pimozide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pimozide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirarubicin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pirarubicin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirenzepine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pirenzepine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pomalidomide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pomalidomide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [147]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ponatinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ponatinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [148]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Posaconazole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Posaconazole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pravastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pravastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Prazosin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Prazosin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [149]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Prednisolone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Prednisolone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [150]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Prednisone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Prednisone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Progesterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Progesterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Propafenone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Propafenone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Propranolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Propranolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Protriptyline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Protriptyline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Prucalopride. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Prucalopride through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [151]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quercetin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [152]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Quetiapine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quetiapine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Quinine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quinine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Raloxifene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Raloxifene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [153]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ramosetron. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ramosetron through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [154]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ranitidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ranitidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ranolazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ranolazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [155]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Regorafenib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Regorafenib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [156]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Reserpine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Reserpine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifampicin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rifampicin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifaximin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rifaximin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [157]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Riociguat. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Riociguat through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [158]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Risperidone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Risperidone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [159]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ritonavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ritonavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [160]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Rivaroxaban. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rivaroxaban through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [161]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Romidepsin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Romidepsin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [162]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Rosuvastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rosuvastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [163]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for S-licarbazepine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of S-licarbazepine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [94]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Saphris. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Saphris through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Saquinavir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Saquinavir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [164]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Saxagliptin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Saxagliptin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sertraline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sertraline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Silodosin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Silodosin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [165]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Simeprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Simeprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Simvastatin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Simvastatin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sitagliptin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sitagliptin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sofosbuvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sofosbuvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [166]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sparfloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sparfloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Spiperone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Spiperone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sumatriptan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sumatriptan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [167]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sunitinib malate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sunitinib malate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [168]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tacrine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tacrine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [169]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tacrolimus. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tacrolimus through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tadalafil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tadalafil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [170]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Talazoparib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Talazoparib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [171]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Telaprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Telaprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Telithromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Telithromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [172]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Temsirolimus. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Temsirolimus through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [173]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tenofovir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir disoproxil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tenofovir disoproxil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenoxicam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tenoxicam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Testosterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Testosterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tetracycline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tetracycline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Thiamphenicol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Thiamphenicol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Thioridazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Thioridazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Timolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Timolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [66]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tolvaptan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tolvaptan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [174]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Topiramate. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Topiramate through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [175]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Topotecan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Topotecan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [176]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Toremifene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Toremifene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tramadol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tramadol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [177]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Trifluoperazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Trifluoperazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Triflupromazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Triflupromazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Trimethoprim. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Trimethoprim through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Triprolidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Triprolidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [178]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Trospium chloride. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Trospium chloride through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [179]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vecuronium. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vecuronium through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [126]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Venetoclax. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Venetoclax through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [180]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Verapamil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Verapamil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [181]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for vildagliptin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of vildagliptin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [182]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vinblastine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vinblastine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [183]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vincristine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vincristine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [184]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vindesine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vindesine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vinorelbine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vinorelbine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [185]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Zidovudine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Zidovudine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ziprasidone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ziprasidone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Zolmitriptan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Zolmitriptan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for 4-Hydroxytamoxifen. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 4-Hydroxytamoxifen through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Asimadoline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Asimadoline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Asunaprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Asunaprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Belotecan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Belotecan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for CBT-1. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of CBT-1 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [186]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Corticosterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Corticosterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dasabuvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dasabuvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Morphine-6-glucuronide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Morphine-6-glucuronide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pazufloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pazufloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [187]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Relugolix. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Relugolix through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Simvastatin acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Simvastatin acid through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [188]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Sitafloxacin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Sitafloxacin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir alafenamide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tenofovir alafenamide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [189]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Vibegron. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Vibegron through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for (Z)-endoxifen. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of (Z)-endoxifen through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [190]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for ABT-263. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ABT-263 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [191]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bisantrene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bisantrene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cholesterol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cholesterol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [192]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for CP-122721. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of CP-122721 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [193]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Curcumin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Curcumin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydrotestosterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [194]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dolastatin 10. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dolastatin 10 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [195]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Fucoxanthin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Fucoxanthin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Gallopamil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Gallopamil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Gepirone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Gepirone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Glecaprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Glecaprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Norverapamil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Norverapamil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [196]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for NSC325663. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of NSC325663 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Paritaprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Paritaprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Roscovitine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Roscovitine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [198]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Staurosporine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Staurosporine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for EDP-322. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of EDP-322 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [199]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Genz 644282. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Genz 644282 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [200]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Naringenin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Naringenin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [152]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Norbuprenorphine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Norbuprenorphine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [201]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Prostaglandin A2. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Prostaglandin A2 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [202]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Substance P. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Substance P through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [203]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Talinolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Talinolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [204]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Velpatasvir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Velpatasvir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Voxilaprevir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Voxilaprevir through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for W-198. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of W-198 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [205]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for YP-005. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of YP-005 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [206]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Abamectin B1A. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Abamectin B1A through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [207]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for AG1478. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of AG1478 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [208]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bouvardin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bouvardin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bunitrolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bunitrolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [209]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cephaeline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cephaeline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Coelenterazine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Coelenterazine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [210]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Cycloheximide. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Cycloheximide through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Desmethylsertraline. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Desmethylsertraline through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for E-guggulsterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of E-guggulsterone through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [211]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Epothilone A. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Epothilone A through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Geneticin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Geneticin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [212]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Metildigoxin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Metildigoxin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Metkephamid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Metkephamid through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for MG-132. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of MG-132 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [213]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for N-desethyl sunitinib. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of N-desethyl sunitinib through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [214]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nafoxidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nafoxidine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nogalamycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nogalamycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Nonactin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nonactin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Okadaic acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Okadaic acid through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pepstatin A. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pepstatin A through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Puromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Puromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [212]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Selamectin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Selamectin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [207]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Silvestrol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Silvestrol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [215]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for SNS-032. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of SNS-032 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [216]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [217]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Azidopine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Azidopine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Bcecf-Am. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bcecf-Am through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Hoechst 33342. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Hoechst 33342 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Leupeptin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Leupeptin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Paraquat. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Paraquat through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tiapamil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tiapamil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [216]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Valinomycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Valinomycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9456. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of XR-9456 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [217]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9504. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of XR-9504 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [217]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9544. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of XR-9544 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [218]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9577. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of XR-9577 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [217]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for [1,1':2',1'']-terphenyl-4,3'',5''-triol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of [1,1':2',1'']-terphenyl-4,3'',5''-triol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [216]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for ABT-737. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ABT-737 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [191]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Alprenolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Alprenolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Apafant. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Apafant through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [219]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Astemizole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Astemizole through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Biricodar. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Biricodar through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [216]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Calphostin C. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Calphostin C through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Dexniguldipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dexniguldipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [197]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Droloxifene. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Droloxifene through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for ELACRIDAR. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ELACRIDAR through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [220]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Flesinoxan. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Flesinoxan through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [221]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydroxybupropion. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Hydroxybupropion through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Isoxicam. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Isoxicam through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for LY335979. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of LY335979 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [222]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Melagatran. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Melagatran through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mibefradil. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mibefradil through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Mithramycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Mithramycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Niguldipine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Niguldipine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for ONT-093. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of ONT-093 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [223]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Pafenolol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pafenolol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Rhodamine 123. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Rhodamine 123 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Roxithromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Roxithromycin through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [172]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for S9788. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of S9788 through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tariquidar. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tariquidar through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [224]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Terfenadine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Terfenadine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Tolafentrine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tolafentrine through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Trans-flupentixol. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Trans-flupentixol through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Valspodar. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Valspodar through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	P-glycoprotein 1 (ABCB1) is a therapeutic target for Ximelagatran. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Ximelagatran through regulating the expression of P-glycoprotein 1 (ABCB1).			[29], [31]